Sac-TMT Combo Extends Lung Cancer Progression Survival
A phase 3 trial found sacituzumab tirumotecan plus Keytruda delayed disease progression versus chemotherapy plus Keytruda in PD-L1-negative lung cancer.
Updated on Nov. 5, 2026 in Cancer
In a phase 3 trial of 455 patients with previously untreated nonsquamous non-small cell lung cancer, sac-TMT plus Keytruda extended median progression-free survival to 15 months, compared with 5.7 months for chemotherapy plus Keytruda. Overall survival data remain immature.
Why it matters
The trial focused on patients with PD-L1-negative tumors, who may be less likely to benefit from immunotherapy alone. Researchers tested whether replacing chemotherapy with sac-TMT could improve outcomes for this group.
The phase 3 randomized trial enrolled 455 patients and reported a 51% reduction in relative risk of progression or death versus chemotherapy plus Keytruda. Overall survival data remain immature, so the effect on survival is not yet known.
The players
OptiTROP-Lung06
A phase 3 randomized trial conducted in China that evaluated sac-TMT plus Keytruda in previously untreated nonsquamous non-small cell lung cancer.
New England Journal of Medicine
A leading peer-reviewed medical journal that published the trial results.
The details
Patients were randomized to receive either sac-TMT plus Keytruda (229 patients) or chemotherapy plus Keytruda (226 patients). Sac-TMT is an antibody-drug conjugate designed to deliver cancer-fighting medication to cells expressing the protein TROP2; grade 3 or higher adverse events occurred in 47.6% of patients receiving the combination.
Timeline
Results reflect a median follow-up of 9.7 months.
The study was published in the New England Journal of Medicine on October 25, 2026.
Health Landscape
The trial builds on Keytruda's established role in treating non-small cell lung cancer, extending that immunotherapy backbone to patients with PD-L1-negative tumors. It tests whether antibody-drug conjugates can strengthen first-line treatment for a group that has historically had fewer options.
For patients with PD-L1-negative lung cancer, the trial suggests a possible new first-line option that may delay disease progression compared with chemotherapy plus Keytruda. The combination's grade 3 or higher adverse event rate of 47.6% is a factor patients and clinicians will need to weigh.
The takeaway
The trial suggests replacing chemotherapy with sac-TMT could extend progression-free survival for patients with PD-L1-negative lung cancer. Whether it improves overall survival will depend on longer follow-up.
Further reading
Explore more on Cancer treatments and research.
